Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues: |
| Protein Sciences | 845.7 | 839.7 | 834.0 | 835.1 | 832.3 | 807.6 | 780.1 | 747.3 |
| Diagnostics and Genomics | 292.6 | 285.2 | 287.2 | 283.8 | 274.8 | 270.2 | 250.7 | 238.6 |
| Total revenues | 1,136.7 | 1,123.6 | 1,119.8 | 1,117.5 | 1,105.6 | 1,076.4 | 1,029.6 | 984.6 |
| Revenue growth [+] | 2.8% | 4.4% | 8.8% | 13.5% | 18.7% | 27.0% | 28.9% | 29.6% |
| Protein Sciences | 1.6% | 4.0% | 6.9% | 11.7% | 18.1% | 26.3% | 30.1% | 31.4% |
| Diagnostics and Genomics | 6.5% | 5.5% | 14.6% | 18.9% | 20.7% | 29.0% | 24.9% | 24.2% |
| Cost of goods sold | 366.9 | 358.1 | 355.1 | 352.4 | 349.1 | 344.3 | 330.7 | 318.4 |
| Gross profit | 769.8 | 765.5 | 764.8 | 765.1 | 756.5 | 732.1 | 698.9 | 666.1 |
| Gross margin | 67.7% | 68.1% | 68.3% | 68.5% | 68.4% | 68.0% | 67.9% | 67.7% |
| Selling, general and administrative [+] | 378.4 | 388.3 | 378.3 | 386.0 | 372.8 | 362.8 | 356.1 | 338.5 |
| Sales and marketing | | 291.6 | 281.7 | 289.3 | | 276.1 | 269.5 | 251.9 |
| General and administrative | 86.8 | | | | 96.6 | | | |
| Research and development | 92.5 | 92.2 | 91.3 | 89.4 | 87.1 | 84.7 | 80.0 | 76.2 |
| EBITDA [+] | 406.2 | 391.2 | 399.8 | 392.7 | 397.7 | 384.5 | 358.4 | 342.8 |
| EBITDA growth | 2.1% | 1.7% | 11.6% | 14.5% | 22.3% | 31.6% | 32.1% | 23.8% |
| EBITDA margin | 35.7% | 34.8% | 35.7% | 35.1% | 36.0% | 35.7% | 34.8% | 34.8% |
| Depreciation | 29.7 | 47.8 | 65.7 | 83.5 | 101.1 | 99.9 | 95.6 | 91.4 |
| EBITA | 376.4 | 343.4 | 334.1 | 309.2 | 296.6 | 284.6 | 262.8 | 251.4 |
| EBITA margin | 33.1% | 30.6% | 29.8% | 27.7% | 26.8% | 26.4% | 25.5% | 25.5% |
| Amortization of intangibles | 77.5 | 58.4 | 38.9 | 19.5 | | | | |
| EBIT [+] | 298.9 | 285.0 | 295.2 | 289.7 | 296.6 | 284.6 | 262.8 | 251.4 |
| EBIT growth | 0.8% | 0.1% | 12.3% | 15.2% | 25.0% | 36.8% | 40.4% | 45.2% |
| EBIT margin | 26.3% | 25.4% | 26.4% | 25.9% | 26.8% | 26.4% | 25.5% | 25.5% |
| Interest expense, net [+] | 7.8 | 10.5 | 10.5 | 10.5 | 10.5 | 13.5 | 13.5 | 13.5 |
| Interest expense | 11.2 | 11.3 | 11.3 | 11.3 | 11.3 | 14.0 | 14.0 | 14.0 |
| Interest income | 3.4 | 0.8 | 0.8 | 0.8 | 0.8 | 0.5 | 0.5 | 0.5 |
| Other income (expense), net | 47.5 | 54.9 | 33.3 | 58.5 | 15.3 | -41.7 | -43.3 | -61.7 |
| Pre-tax income | 338.7 | 329.4 | 318.0 | 337.7 | 301.4 | 229.4 | 206.0 | 176.2 |
| Income taxes | 53.2 | 57.5 | 56.2 | 53.9 | 38.3 | 13.6 | 4.9 | 1.0 |
| Tax rate | 15.7% | 17.5% | 17.7% | 16.0% | 12.7% | 5.9% | 2.4% | |
| Minority interest | | | | -8.1 | -9.0 | -9.7 | -9.4 | -1.5 |
| Net income | 285.3 | 271.3 | 261.8 | 292.0 | 272.1 | 225.5 | 210.5 | 176.6 |
| Net margin | 25.1% | 24.1% | 23.4% | 26.1% | 24.6% | 20.9% | 20.4% | 17.9% |
| |
| Basic EPS [+] | $2.23 | $2.13 | $2.05 | $2.29 | $2.13 | $1.77 | $2.16 | $2.60 |
| Growth | 4.8% | 19.8% | -4.9% | -12.0% | 2.9% | -62.9% | -52.6% | -59.9% |
| Diluted EPS [+] | $2.17 | $2.06 | $1.97 | $2.19 | $2.04 | $1.70 | $2.06 | $2.49 |
| Growth | 6.5% | 21.2% | -4.2% | -12.0% | 2.6% | -63.1% | -53.1% | -60.3% |
| |
| Dividends per share [+] | $0.72 | $0.56 | $0.72 | $0.80 | $0.80 | $0.08 | $0.80 | $0.96 |
| Growth | -10.0% | 600.0% | -10.0% | -16.7% | -16.7% | -95.8% | -37.5% | 0.0% |
| |
| Shares outstanding (basic) [+] | 127.7 | 127.6 | 127.6 | 127.6 | 127.6 | 127.1 | 97.5 | 67.9 |
| Growth | 0.1% | 0.4% | 30.8% | 87.9% | 88.3% | 229.5% | 153.8% | 77.3% |
| Shares outstanding (diluted) [+] | 131.4 | 132.0 | 132.6 | 133.3 | 133.5 | 132.9 | 102.1 | 71.0 |
| Growth | -1.5% | -0.7% | 29.8% | 87.8% | 88.8% | 231.6% | 156.8% | 79.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|